Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2019-10, Vol.30, p.v549-v550 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | v550 |
|---|---|
| container_issue | |
| container_start_page | v549 |
| container_title | Annals of oncology |
| container_volume | 30 |
| creator | Knispel, S. Gassenmaier, M. Menzies, A.M. Loquai, C. Johnson, D.B. Franklin, C. Gutzmer, R. Hassel, J.C. Weishaupt, C. Eigentler, T. Schummer, P. Kiecker, F. Owen, C. Schmidgen, M.I. Kähler, K.C. Cann, C.G. Niebel, D. Mohr, P. Schadendorf, D. Zimmer, L. |
| description | |
| doi_str_mv | 10.1093/annonc/mdz255.034 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdz255_034</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_annonc_mdz255_034</sourcerecordid><originalsourceid>FETCH-LOGICAL-c854-f456723f6fef2f3b058c601896eb15cc038908b825ca988c6f157932654e98693</originalsourceid><addsrcrecordid>eNotkL1uwjAYRT20UunPA3TzCEPAjmNjjxW0BQmJDtkjx3xu3BInsk0rOvfBG6DTvdK5usNB6JGSKSWKzbT3nTezdveTcz4lrLhCI6Jyls05K27QbYwfhBChcjVCv9tDMl0LuLO418mBTxF_u9Rg2MOXTrDDm-UKpwDnfibWhZiyvfOAkw7vcAKpgaD7Ix6X5QR3Ab8tM4prHQfk2vYwTE0D5rPvnE_Y-cbVLnUh4vF6sZ7co2ur9xEe_vMOlS_P5WKVbbav68XTJjOSF5ktuJjnzAoLNresJlwaQahUAmrKjSFMKiJrmXOjlRyYpXyuWC54AUoKxe4Qvdya0MUYwFZ9cK0Ox4qS6mSuupirLuaqwRz7A2inZlk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Knispel, S. ; Gassenmaier, M. ; Menzies, A.M. ; Loquai, C. ; Johnson, D.B. ; Franklin, C. ; Gutzmer, R. ; Hassel, J.C. ; Weishaupt, C. ; Eigentler, T. ; Schummer, P. ; Kiecker, F. ; Owen, C. ; Schmidgen, M.I. ; Kähler, K.C. ; Cann, C.G. ; Niebel, D. ; Mohr, P. ; Schadendorf, D. ; Zimmer, L.</creator><creatorcontrib>Knispel, S. ; Gassenmaier, M. ; Menzies, A.M. ; Loquai, C. ; Johnson, D.B. ; Franklin, C. ; Gutzmer, R. ; Hassel, J.C. ; Weishaupt, C. ; Eigentler, T. ; Schummer, P. ; Kiecker, F. ; Owen, C. ; Schmidgen, M.I. ; Kähler, K.C. ; Cann, C.G. ; Niebel, D. ; Mohr, P. ; Schadendorf, D. ; Zimmer, L.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>DOI: 10.1093/annonc/mdz255.034</identifier><language>eng</language><ispartof>Annals of oncology, 2019-10, Vol.30, p.v549-v550</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Knispel, S.</creatorcontrib><creatorcontrib>Gassenmaier, M.</creatorcontrib><creatorcontrib>Menzies, A.M.</creatorcontrib><creatorcontrib>Loquai, C.</creatorcontrib><creatorcontrib>Johnson, D.B.</creatorcontrib><creatorcontrib>Franklin, C.</creatorcontrib><creatorcontrib>Gutzmer, R.</creatorcontrib><creatorcontrib>Hassel, J.C.</creatorcontrib><creatorcontrib>Weishaupt, C.</creatorcontrib><creatorcontrib>Eigentler, T.</creatorcontrib><creatorcontrib>Schummer, P.</creatorcontrib><creatorcontrib>Kiecker, F.</creatorcontrib><creatorcontrib>Owen, C.</creatorcontrib><creatorcontrib>Schmidgen, M.I.</creatorcontrib><creatorcontrib>Kähler, K.C.</creatorcontrib><creatorcontrib>Cann, C.G.</creatorcontrib><creatorcontrib>Niebel, D.</creatorcontrib><creatorcontrib>Mohr, P.</creatorcontrib><creatorcontrib>Schadendorf, D.</creatorcontrib><creatorcontrib>Zimmer, L.</creatorcontrib><title>Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)</title><title>Annals of oncology</title><issn>0923-7534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNotkL1uwjAYRT20UunPA3TzCEPAjmNjjxW0BQmJDtkjx3xu3BInsk0rOvfBG6DTvdK5usNB6JGSKSWKzbT3nTezdveTcz4lrLhCI6Jyls05K27QbYwfhBChcjVCv9tDMl0LuLO418mBTxF_u9Rg2MOXTrDDm-UKpwDnfibWhZiyvfOAkw7vcAKpgaD7Ix6X5QR3Ab8tM4prHQfk2vYwTE0D5rPvnE_Y-cbVLnUh4vF6sZ7co2ur9xEe_vMOlS_P5WKVbbav68XTJjOSF5ktuJjnzAoLNresJlwaQahUAmrKjSFMKiJrmXOjlRyYpXyuWC54AUoKxe4Qvdya0MUYwFZ9cK0Ox4qS6mSuupirLuaqwRz7A2inZlk</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Knispel, S.</creator><creator>Gassenmaier, M.</creator><creator>Menzies, A.M.</creator><creator>Loquai, C.</creator><creator>Johnson, D.B.</creator><creator>Franklin, C.</creator><creator>Gutzmer, R.</creator><creator>Hassel, J.C.</creator><creator>Weishaupt, C.</creator><creator>Eigentler, T.</creator><creator>Schummer, P.</creator><creator>Kiecker, F.</creator><creator>Owen, C.</creator><creator>Schmidgen, M.I.</creator><creator>Kähler, K.C.</creator><creator>Cann, C.G.</creator><creator>Niebel, D.</creator><creator>Mohr, P.</creator><creator>Schadendorf, D.</creator><creator>Zimmer, L.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201910</creationdate><title>Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)</title><author>Knispel, S. ; Gassenmaier, M. ; Menzies, A.M. ; Loquai, C. ; Johnson, D.B. ; Franklin, C. ; Gutzmer, R. ; Hassel, J.C. ; Weishaupt, C. ; Eigentler, T. ; Schummer, P. ; Kiecker, F. ; Owen, C. ; Schmidgen, M.I. ; Kähler, K.C. ; Cann, C.G. ; Niebel, D. ; Mohr, P. ; Schadendorf, D. ; Zimmer, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c854-f456723f6fef2f3b058c601896eb15cc038908b825ca988c6f157932654e98693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Knispel, S.</creatorcontrib><creatorcontrib>Gassenmaier, M.</creatorcontrib><creatorcontrib>Menzies, A.M.</creatorcontrib><creatorcontrib>Loquai, C.</creatorcontrib><creatorcontrib>Johnson, D.B.</creatorcontrib><creatorcontrib>Franklin, C.</creatorcontrib><creatorcontrib>Gutzmer, R.</creatorcontrib><creatorcontrib>Hassel, J.C.</creatorcontrib><creatorcontrib>Weishaupt, C.</creatorcontrib><creatorcontrib>Eigentler, T.</creatorcontrib><creatorcontrib>Schummer, P.</creatorcontrib><creatorcontrib>Kiecker, F.</creatorcontrib><creatorcontrib>Owen, C.</creatorcontrib><creatorcontrib>Schmidgen, M.I.</creatorcontrib><creatorcontrib>Kähler, K.C.</creatorcontrib><creatorcontrib>Cann, C.G.</creatorcontrib><creatorcontrib>Niebel, D.</creatorcontrib><creatorcontrib>Mohr, P.</creatorcontrib><creatorcontrib>Schadendorf, D.</creatorcontrib><creatorcontrib>Zimmer, L.</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knispel, S.</au><au>Gassenmaier, M.</au><au>Menzies, A.M.</au><au>Loquai, C.</au><au>Johnson, D.B.</au><au>Franklin, C.</au><au>Gutzmer, R.</au><au>Hassel, J.C.</au><au>Weishaupt, C.</au><au>Eigentler, T.</au><au>Schummer, P.</au><au>Kiecker, F.</au><au>Owen, C.</au><au>Schmidgen, M.I.</au><au>Kähler, K.C.</au><au>Cann, C.G.</au><au>Niebel, D.</au><au>Mohr, P.</au><au>Schadendorf, D.</au><au>Zimmer, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)</atitle><jtitle>Annals of oncology</jtitle><date>2019-10</date><risdate>2019</risdate><volume>30</volume><spage>v549</spage><epage>v550</epage><pages>v549-v550</pages><issn>0923-7534</issn><doi>10.1093/annonc/mdz255.034</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2019-10, Vol.30, p.v549-v550 |
| issn | 0923-7534 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdz255_034 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T08%3A55%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20of%20patients%20with%20elevated%20LDH%20treated%20with%20first-line%20targeted%20therapy%20(TT)%20or%20PD-1%20based%20immune%20checkpoint%20inhibitors%20(ICI)&rft.jtitle=Annals%20of%20oncology&rft.au=Knispel,%20S.&rft.date=2019-10&rft.volume=30&rft.spage=v549&rft.epage=v550&rft.pages=v549-v550&rft.issn=0923-7534&rft_id=info:doi/10.1093/annonc/mdz255.034&rft_dat=%3Ccrossref%3E10_1093_annonc_mdz255_034%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |